pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104
Authors
Keywords
Biomarker, EGFR, Erlotinib, Pancreatic cancer
Journal
BMC CANCER
Volume 14, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-08-28
DOI
10.1186/1471-2407-14-624
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012
- (2013) C. Verslype et al. ANNALS OF ONCOLOGY
- Changing the Way We Do Business: Recommendations to Accelerate Biomarker Development in Pancreatic Cancer
- (2013) M. A. Tempero et al. CLINICAL CANCER RESEARCH
- Therapeutic Advances in Pancreatic Cancer
- (2013) Andrew Scott Paulson et al. GASTROENTEROLOGY
- Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
- (2013) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer
- (2013) Stefan Boeck et al. JOURNAL OF GASTROENTEROLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
- (2012) S Boeck et al. BRITISH JOURNAL OF CANCER
- EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis
- (2012) Christine M. Ardito et al. CANCER CELL
- Systemic treatment of advanced pancreatic cancer
- (2012) Volker Heinemann et al. CANCER TREATMENT REVIEWS
- Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)
- (2012) Volker Heinemann et al. GUT
- Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer
- (2012) Takeshi Ogura et al. JOURNAL OF GASTROENTEROLOGY
- Overexpression of p53 protein in human tumors
- (2012) Keiji Inoue et al. Medical Molecular Morphology
- Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing
- (2012) Winnie S. Liang et al. PLoS One
- A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
- (2012) Eric A. Collisson et al. Cancer Discovery
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy
- (2011) S. T. Kim et al. MOLECULAR CANCER THERAPEUTICS
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer
- (2010) Gilda da Cunha Santos et al. CANCER
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
- (2010) Philip A. Philip et al. JOURNAL OF CLINICAL ONCOLOGY
- PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
- (2009) Fotios Loupakis et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search